|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
FY2018
12 months to Dec 31, 2018
|
|
|---|---|---|---|---|
| Revenue | ||||
| Sublicense revenue | ||||
| Grant revenue | ||||
| Total revenue | ||||
| Operating expenses: | ||||
| Research and development | ||||
| General and administrative | ||||
| Total operating expenses | ||||
| Loss from operations | ||||
| Other (expense) income: | ||||
| Loss from remeasurement of development derivative liability | ||||
| Interest income | ||||
| Interest expense | ||||
| Foreign exchange gain | ||||
| Change in fair value of warrant liability | ||||
| Change in fair value of derivative liability | ||||
| Total other expense | ||||
| Net loss before income taxes | ||||
| Provision for income taxes | ||||
| Net loss | ||||
| Net loss per common share, basic and diluted (in usd per share) | ||||
| Weighted-average common shares outstanding, basic and diluted (in shares) | ||||
| Net loss per common share, basic (in usd per share) | ||||
| Net loss per common share, diluted (in usd per share) | ||||
| Weighted-average common shares outstanding, basic (in shares) | ||||
| Weighted-average common shares outstanding, diluted (in shares) |
Loading...
